Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results

Genetics Investing

Myriad Genetics (NASDAQ:MYGN), a global leader in molecular diagnostics and personalized medicine, today announced financial results for its fiscal third-quarter 2018, provided an update on recent business highlights and raised its fiscal year 2018 financial guidance. As quoted in the press release: “We saw strong results in the third quarter with financial performance once again …

As quoted in the press release:

“We saw strong results in the third quarter with financial performance once again exceeding our expectations due to better than anticipated hereditary cancer volumes, strong new product volume growth and the success of our Elevate 2020 program,” said Mark C. Capone, president and CEO, Myriad Genetics. “Our diversification efforts achieved record results in the third quarter, with new products now representing 71 percent of sample volume and 36 percent of revenue. And the landmark GeneSight^®clinical trial results have led to our first commercial coverage decision. Given that this new product growth is being built upon a solid hereditary cancer foundation, we are raising our financial guidance for fiscal year 2018.”

Click here to read the full press release.

cancer clinical trial results coverage diagnostics financial results genetics guidance molecular diagnostics myriad genetics personalized medicine Genetics Investing